GRCE Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Grace Therapeutics Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerGRCE

Market Cap41.4M

Cash RunwayRunway > 12 months

Next Catalyst2027-02

Public Research Snapshot

Grace Therapeutics Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Aprocitentan 12.5 mg in Resistant Hypertension (Phase 3).

Pipeline

Asset	Indication	Modality	Stage	Public Note
Real-World Experience Study of Elagolix For the Treatment of Endometriosis in Canada	Endometriosis	n/a	n/a	Public pipeline row
Aprocitentan 12.5 mg	Resistant Hypertension	n/a	Phase 3	Public pipeline row
DISC-3405	Polycythemia Vera (PV)	n/a	Phase 2	Public pipeline row
Auxora (Part 1)	Pneumonia	n/a	Phase 2	Public pipeline row
Sotagliflozin	Diabetic Nephropathies \| Kidney Failure, Chronic \| Diabetes Mellitus Type 1 \| Heart Failure	n/a	Phase 3	Public pipeline row

Catalyst Preview

Company	Ticker	Catalyst	Timing	Asset	Confidence
		Clinical Trial Completion	2027-02	DISC-3405	Low
		Clinical Trial Completion	2028-12	Sotagliflozin	Low

Cash Runway Preview

Estimated cash runway: Runway > 12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT03541174	Phase 3	COMPLETED	730	2021-05-14
NCT04345614	Phase 2	COMPLETED	314	2021-06-28
NCT04080856	n/a	COMPLETED	100	2021-09-27
NCT06985147	Phase 2	RECRUITING	60	2027-02
NCT06217302	Phase 3	RECRUITING	150	2028-12

Scientific Context

asset_name | Aprocitentan 12.5 mg
clinical_stage | Phase 3
clinical_stage | Phase 3
indication | Resistant Hypertension
indication | Resistant Hypertension

Want the full GRCE research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.